The probe is directed at all CAR-Ts currently ... positive lymphoma – in patients who had received both types of CAR-T therapy. The regulator highlighted the products by name, including Bristol- ...

When the symptoms and inflammation are not brought under control, they can cause organ damage. Like other cell therapies, CAR T cell therapy uses a modified cell either from the patient or from a ...

CAR-T cell therapy has revolutionized the treatment of relapsed and refractory B-acute lymphoblastic leukemia (B-ALL), with remission rates reaching as high as 90%. This therapy modifies a patient ...

While CAR T cell therapy—a personalized form of cancer immunotherapy first successfully developed by Carl June, MD, and his team at Penn—has revolutionized treatment for many blood cancers ...

Researchers were perplexed when the Food and Drug Administration announced it was investigating whether CAR-T therapy, one of the most effective treatments for blood cancers, could cause lymphoma.

CAR T cell therapy against CD19 and B cell maturation antigen (BCMA) is a potent immunotherapy for treating advanced B cell malignancies. It comes with a unique toxicity profile that includes cytokine ...

Chimeric antigen receptor T-cell therapy, or CAR-T cell therapy, is one type of immunotherapy. Sometimes likened to a "smart drug" or "living drug," CAR-T cell therapy relies on genetically ...

Despite these advancements, more than 50% of patients with lymphoma do not have long-term remission with anti-CD19 CAR T-cell therapy. These patients have limited treatment options and poor prognoses.

An obvious next step in the development and growth of CAR T-cell therapies has been the jump to solid tumors. Because of inherent differences between hematologic and solid malignancies ...

Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of refractory or relapsed leukemia and hematologic malignancies, particularly over the past decade. Despite its ...

A phase I study of a next-generation CAR T cell therapy showed a 52 percent complete remission rate for patients with relapsed/refractory lymphoma. A next-generation "armored" CAR T cell therapy ...